ELAC2
Zinc phosphodiesterase ELAC protein 2
Protein Summary
Zinc phosphodiesterase, which displays mitochondrial tRNA 3'-processing endonuclease activity. Involved in tRNA maturation, by removing a 3'-trailer from precursor tRNA. The protein encoded by this gene has a C-terminal domain with tRNA 3′ processing endoribonuclease activity, which catalyzes the removal of the 3' trailer from precursor tRNAs. The protein also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1), and reduced expression can suppress transforming growth factor-beta induced growth arrest. Mutations in this gene result in an increased risk of prostate cancer. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2009]
- ENST00000338034
- ENSP00000337445
- ENSG00000006744
- ENST00000426905
- ENSP00000405223
- HPC2
- ELC2
- HPC2
- COXPD17
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
kinase perturbation | 0.96 | ||
disease perturbation | 0.9 | ||
gene perturbation | 0.85 | ||
virus perturbation | 0.79 | ||
transcription factor binding site profile | 0.77 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 96.2 (req: < 5)
Gene RIFs: 40 (req: <= 3)
Antibodies: 176 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 96.2 (req: >= 5)
Gene RIFs: 40 (req: > 3)
Antibodies: 176 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 7
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0